Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: ACS Chem Neurosci. 2020 Jun 19;11(13):1937–1943. doi: 10.1021/acschemneuro.0c00093

Figure 3.

Figure 3.

The brain bioavailability of largazole. A. Dose-response analysis of histone hyperacetylation in brain (4 h; ip). B. In vivo monitoring of largazole thiol levels in excised whole-brain tissue (error bars represent SEM, n = 2). C. Bdnf expression in brain tissue after 12 h treatment with largazole (ip 50 mg/kg) vs control assessed by RT-qPCR (TaqMan; Actin was the endogenous control). Error bars represent SEM, n = 2. The asterisk denotes significance of p ≤ 0.05 relative to solvent control using two-tailed unpaired t test.